Danaher announced that its President and CEO, Rainer Blair, will comment tomorrow on the company’s fourth quarter 2022 performance in a presentation at the J.P. Morgan Healthcare Conference at 1:30 p.m. PT. For the fourth quarter 2022, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year. The company expects estimated non-GAAP core revenue growth in the high-single digit percent range, which would be above the company’s previously announced guidance of flat to a low-single digit percent decline. Non-GAAP base business core revenue growth is expected to be in the high-single digit percent range, which is in line with the company’s previously announced guidance. Blair stated, "Our team successfully navigated a challenging environment to deliver better-than-expected fourth quarter results and a strong finish to 2022. We are very pleased with the continued strength in our base business which had another quarter of high-single digit core revenue growth. We also saw better than expected growth in Cepheid’s molecular diagnostics business driven by more than $1 billion in respiratory testing revenue during the quarter." Blair continued, "Our fourth quarter results highlight the resilience and attractive end-market positioning of the businesses that make up Danaher today. Looking ahead, we believe the strength of the portfolio, combined with our outstanding team and the power of the Danaher Business System will enable us to continue delivering sustainable, long-term shareholder value for many years to come."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DHR:
